Browse ITGA11

Summary
SymbolITGA11
Nameintegrin, alpha 11
Aliases HsT18964; Integrin alpha-11
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF01839 FG-GAP repeat
PF08441 Integrin alpha
PF00092 von Willebrand factor type A domain
Function

Integrin alpha-11/beta-1 is a receptor for collagen.

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0006929 substrate-dependent cell migration
GO:0007160 cell-matrix adhesion
GO:0007229 integrin-mediated signaling pathway
GO:0007517 muscle organ development
GO:0030198 extracellular matrix organization
GO:0031589 cell-substrate adhesion
GO:0033627 cell adhesion mediated by integrin
GO:0038065 collagen-activated signaling pathway
GO:0043062 extracellular structure organization
Molecular Function GO:0005518 collagen binding
GO:0038064 collagen receptor activity
GO:0098631 protein binding involved in cell adhesion
GO:0098634 protein binding involved in cell-matrix adhesion
GO:0098639 collagen binding involved in cell-matrix adhesion
Cellular Component GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0008305 integrin complex
GO:0030055 cell-substrate junction
GO:0034681 integrin alpha11-beta1 complex
GO:0043235 receptor complex
GO:0098636 protein complex involved in cell adhesion
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion
hsa04512 ECM-receptor interaction
hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-1474244: Extracellular matrix organization
R-HSA-216083: Integrin cell surface interactions
Summary
SymbolITGA11
Nameintegrin, alpha 11
Aliases HsT18964; Integrin alpha-11
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ITGA11 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolITGA11
Nameintegrin, alpha 11
Aliases HsT18964; Integrin alpha-11
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ITGA11 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolITGA11
Nameintegrin, alpha 11
Aliases HsT18964; Integrin alpha-11
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ITGA11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9470.0413
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9120.344
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9670.188
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.50.231
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9570.636
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0810.976
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1660.768
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1840.864
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6460.605
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8020.49
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.6310.0574
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2570.225
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ITGA11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.48.2-0.81
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.410.2-2.81
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.1023.10.223
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolITGA11
Nameintegrin, alpha 11
Aliases HsT18964; Integrin alpha-11
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ITGA11. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolITGA11
Nameintegrin, alpha 11
Aliases HsT18964; Integrin alpha-11
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ITGA11. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ITGA11.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolITGA11
Nameintegrin, alpha 11
Aliases HsT18964; Integrin alpha-11
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ITGA11. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolITGA11
Nameintegrin, alpha 11
Aliases HsT18964; Integrin alpha-11
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ITGA11 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolITGA11
Nameintegrin, alpha 11
Aliases HsT18964; Integrin alpha-11
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ITGA11 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolITGA11
Nameintegrin, alpha 11
Aliases HsT18964; Integrin alpha-11
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ITGA11 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.